Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of
somatropin (Norditropin®) on final height in children with Noonan syndrome having being
treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal
final height in the original trial S/GHD/004/NOO.